相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
Hong Sun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2022)
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
Masato Furuhashi et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2022)
Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Bruno Verges et al.
DIABETES & METABOLISM (2022)
Insight into the Evolving Role of PCSK9
Mateusz Maliglowka et al.
METABOLITES (2022)
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
Andrei C. Sposito et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes
Li Song et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes
Domenico Trico et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2022)
Molecular and cellular biology of PCSK9: impact on glucose homeostasis
Segbede E. R. Tcheoubi et al.
JOURNAL OF DRUG TARGETING (2022)
Sex difference in circulating PCSK9 and its clinical implications
Fang Jia et al.
FRONTIERS IN PHARMACOLOGY (2022)
Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells
Amjad Ali et al.
ENDOCRINE (2022)
Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes
Samira Taghizadeh Jazdani et al.
BMC RESEARCH NOTES (2021)
Diabetes, Lipids, and CV Risk
Jan Skrha
CURRENT ATHEROSCLEROSIS REPORTS (2021)
New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation
Die Hu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)
Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression
Bruno Verges et al.
DIABETES CARE (2021)
Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study
Stephen J. Nicholls et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Andrei C. Sposito et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Gregory G. Schwartz et al.
DIABETES CARE (2021)
Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice
Marie-Line Peyot et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2021)
Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/low-density lipoprotein receptor (LDLR)
Jingquan Ji et al.
BIOENGINEERED (2021)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2020 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2020)
Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing toll-like receptor 4/nuclear factor-kappa B
Lei Lei et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2020)
Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
Jia Peng et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Combined intake of glucose-and lipid-lowering medications further elevates plasma levels of PCSK9 in type 2 diabetes patients
Samir Awadallah et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
Lorenzo Da Dalt et al.
EUROPEAN HEART JOURNAL (2019)
Circulating PCSK9 concentrations are increased in postmenopausal women with the metabolic syndrome
Nutjaree Jeenduang
CLINICA CHIMICA ACTA (2019)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K. Ray et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
Kausik K. Ray et al.
CARDIOVASCULAR DIABETOLOGY (2019)
P704Nanoliposomal anti-PCSK9 vaccine ameliorates glucose intolerance and insulin resistance in diabetic rats
A A Momtazi-Borojeni et al.
EUROPEAN HEART JOURNAL (2019)
Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control
Dragana Bojanin et al.
ATHEROSCLEROSIS (2019)
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
Lawrence A. Leiter et al.
DIABETES CARE (2019)
GLP-1 receptor agonists and cardiovascular outcome trials: An update
Eirini Andrikou et al.
HELLENIC JOURNAL OF CARDIOLOGY (2019)
C679X loss-of-function PCSK9 variant is associated with lower fasting glucose in black South African adolescents: Birth to Twenty Plus Cohort
Tinashe Chikowore et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY (2019)
Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism
Sheng-Hua Yang et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367
Ye-Xuan Cao et al.
DIABETES CARE (2018)
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials
Om P. Ganda et al.
DIABETES OBESITY & METABOLISM (2018)
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
Kausik K. Ray et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
Ye-Xuan Cao et al.
DIABETES OBESITY & METABOLISM (2018)
Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population
Wen Guo et al.
LIPIDS IN HEALTH AND DISEASE (2018)
Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
Henry N. Ginsberg et al.
DIABETES THERAPY (2018)
Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
Henry N. Ginsberg et al.
DIABETES THERAPY (2018)
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Robert P. Giugliano et al.
CIRCULATION (2018)
C679X loss-of-function PCSK9 variant lowers fasting glucose levels in a black South African population: A longitudinal study
Tinashe Chikowore et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low-Density Lipoprotein Cholesterol
Thorsten M. Leucker et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Matthieu Chodorge et al.
SCIENTIFIC REPORTS (2018)
Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials
L. A. Leiter et al.
DIABETIC MEDICINE (2018)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years
Luiz Sergio F. de Carvalho et al.
DIABETES CARE (2018)
Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes
Stephanie Laugier-Robiolle et al.
DIABETES OBESITY & METABOLISM (2017)
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
Dirk J. Blom et al.
DIABETES OBESITY & METABOLISM (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
Michael J. Koren et al.
JAMA CARDIOLOGY (2017)
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial
Lawrence A. Leiter et al.
DIABETES OBESITY & METABOLISM (2017)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females
Hayder Hasan et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2017)
The mechanisms of action of metformin
Graham Rena et al.
DIABETOLOGIA (2017)
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II
Lawrence A. Leiter et al.
DIABETES OBESITY & METABOLISM (2017)
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9
Nabil G. Seidah et al.
PHARMACOLOGICAL REVIEWS (2017)
Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes
Sheng-Hua Yang et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2016)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes A Meta-analysis
Luca A. Lotta et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
National Lipid Association Annual Summary of Clinical Lipidology 2016
Harold E. Bays et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Dean J. Kereiakes et al.
AMERICAN HEART JOURNAL (2015)
Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9
Ji Miao et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis
Amelie Bonnefond et al.
DIABETOLOGIA (2015)
Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk
Yascara G. Luna Saavedra et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
Ymene Nekaies et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The effect of insulin on circulating PCSK9 in postmenopausal obese women
Zuhier Awan et al.
CLINICAL BIOCHEMISTRY (2014)
Statin treatment and new-onset diabetes: A review of proposed mechanisms
Marilyne Brault et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
Combined Administration of RG7652, a Recombinant Human Monoclonal Antibody Against PCSK9, and Atorvastatin Does Not Result in Reduction of Immune Function
Thomas R. Gelzleichter et al.
TOXICOLOGICAL SCIENCES (2014)
Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype
Zuhier Awan et al.
CANADIAN JOURNAL OF CARDIOLOGY (2013)
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
Ding Ai et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study
M. C. G. J. Brouwers et al.
ATHEROSCLEROSIS (2011)
Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients
Bertrand Cariou et al.
ATHEROSCLEROSIS (2010)
A new method for measurement of total plasma PCSK9: clinical applications
Genevieve Dubuc et al.
JOURNAL OF LIPID RESEARCH (2010)
Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
Alexis Baass et al.
CLINICAL CHEMISTRY (2009)
Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors
Lena Persson et al.
ENDOCRINOLOGY (2009)
Diabetes alters LDL receptor and PCSK9 expression in rat liver
Melissa Niesen et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
LANCET (2008)
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Cristen J. Willer et al.
NATURE GENETICS (2008)
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
P Costet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The Dallas Heart Study: A population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health
RG Victor et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes
JD Horton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice
KN Maxwell et al.
JOURNAL OF LIPID RESEARCH (2003)
分享论文
